Efficacy and Safety of Intravenous Treatment of Tuberculosis

Yuria-Pharm166 enrolled

Overview

This Open-label, Randomized, Multicenter, Controlled, Parallel, Comparative Study will compare the efficacy and safety of intravenous treatment with Isoniazid, Rifampicin, Ethambutol first two months of intensive phase of tuberculosis treatment and the treatment with the oral forms of Isoniazid, Rifampicin, Ethambutol first two months of intensive phase of tuberculosis treatment for Patients With Widespread Destructive Pulmonary Tuberculosis With Bacterial Excretion.

There are two groups of patients with first diagnosed widespread destructive pulmonary tuberculosis with bacterial excretion. The first group receives intravenous treatment with Isoniazid, Rifampicin, Ethambutol first two months of intensive phase of tuberculosis treatment. The second group gets oral forms of Isoniazid, Rifampicin, Ethambutol first two months of intensive phase of Tuberculosis treatment. Then both groups receive oral treatment of tuberculosis according to the known scheme. Up to 318 participants will be randomized into this study, with 159 participants being randomized to the control arm and 159 participants being randomized to the experimental arm. It Supposed that not less than 254 participants will finish the study (about 127 participants in each arm) and their results will be included in the statistical analysis. While the intensive phase participants of both arms will be hospitalized in the Tuberculosis Dispensary.

Study Type

OBSERVATIONAL

Enrollment

166

Conditions

Tuberculosis, Pulmonary

Interventions

IsoniazidDRUG

Solution for injections, 100 mg/ml, 5 ml. Participants will get the dosage according to the instruction for use.

RifampicinDRUG

Participants will get the dosage according to the instruction for use.

EthambutolDRUG

Participants will get the dosage according to the instruction for use.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. men and women; 2. The age of 18 - 65 years inclusive; 3. Patients diagnosed with: first diagnosed pulmonary tuberculosis; 4. Patients with at least one positive result of a microbiological study of the sputum on the Mycobacterium tuberculosis (during the screening, the results of a microbiological sputum examination on an Mycobacterium tuberculosis up to 7 days old can be used); 5. Patients with radiographically and optionally CT confirmed cavity / cavities of destruction in the lungs, as well as a widespread tuberculosis process (occupying at least 2 segments of the lungs) (during the screening, the results of X-ray examination of the chest up to 7 days old can be used ); 6. For women with reproductive potential - negative result of urine test for pregnancy and consent to use a reliable method of contraception before the end of the study; 7. Provided informed written consent of the patient to participate in the study; 8. The patient's ability to adequately cooperate in the research process; 9. Patients with negative analysis of GenXpert MBT / RIF (at the time of screening, analysis results not older than 7 days may be used); 10. Oral consent of the patient to stop using alcohol during the study period. Exclusion Criteria: 1. Patients who, according to the results of a sputum test using the GenXpert MBT / RIF method, are determined to be resistant to rifampicin. 2. Pregnancy, lactation; 3. Epilepsy and other diseases, which are accompanied by a tendency to convulsive seizures; 4. Severe psychosis; 5. Poliomyelitis (including in the anamnesis); 6. Diseases of the cardiovascular system, respiratory system, diabetes mellitus, impaired liver function, kidney, thyroid gland, vision, the presence of concomitant diseases or acute conditions, which, according to the researcher, do not allow the patient to participate in this study; 7. HIV infection; 8. Intolerance (including history) of any of the drugs studied; 9. Participation in any other clinical trial at the time of inclusion in this study and for the last 30 days before the date of screening.

Locations (9)

Regional Clinical Antituberculosis Dispensary

Chernivtsi, Ukraine

Regional phthisiopulmonary center

Ivano-Frankivsk, Ukraine

Regional Antituberculosis Dispensary №1

Kharkiv, Ukraine

Regional Antituberculosis Dispensary

Outcomes

Primary Outcomes

Percentage of patients with negative results of sputum analysis on Mycobacterium tuberculosis .

Percentage of patients with negative results of sputum analysis on Mycobacterium tuberculosis in the main and control groups.

Time frame: Тhe end of the 1st month from the start of treatment (after taking 30 doses of each drug by the patient)

Secondary Outcomes

Time until the negative result of the Mycobacterium tuberculosis tests is obtained.

Time until the negative result of sputum Mycobacterium tuberculosis tests is obtained for each patient.

Time frame: 2 weeks - 3 months

Combined percentage ratio of patients with negative results of Mycobacterium tuberculosis analysis and clinical improvement.

Combined percentage ratio of patients who have negative results of sputum analysis on Mycobacterium tuberculosis and clinical improvement at the same time.

Time frame: 2 months after the start of treatment (after taking the patient 60 doses of each preparation of the intensive phase).

Combined percentage of patients with no response to treatment in 12 months.

Combined percentage ratio of patients with no response to treatment in 12 months.

Time frame: 12 months after the start of treatment (13 months after initiation of treatment for patients who still have the positive results of the sputum analysis on Mycobacterium tuberculosis after taking 60 doses of each preparation of the intensive phase).

Combined percentage ratio of patients with no response to treatment in 18 months.

Time frame: 18 months after the start of treatment (19 months after initiation of treatment for patients who still have the positive results of the sputum analysis on Mycobacterium tuberculosis after taking 60 doses of each preparation of the intensive phase).

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.